A randomized, placebo-controlled, double blind trial to study the effects of Etidronate on ectopic CALCIfication in FAhr’s Disease or syndrome: CALCIFADE trial

Conditions

Fahr's disease, Fahr's syndrome

Brief summary

Change in cognitive functioning of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline.

Detailed description

Change in mobility of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in psychiatric symptoms of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in daily functioning of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in quality of life of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in calcification in the brain of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline.

Related papers

No related papers found yet.

Interventions

DRUGETIDRONATE DISODIUM ORAL CAPSULES 400 MG PLACEBO

DRUGETIDRONATE DISODIUM ORAL CAPSULES 400 MG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in cognitive functioning of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline.	—

Secondary

Measure	Time frame
Change in mobility of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in psychiatric symptoms of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in daily functioning of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in quality of life of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in calcification in the brain of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline.	—

Measure

Time frame

Change in mobility of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in psychiatric symptoms of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in daily functioning of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in quality of life of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline., Change in calcification in the brain of patients with Fahr’s disease or syndrome treated with etidronate or placebo between baseline and 12 months after baseline.

—

Countries

Netherlands

Outcome results

None listed